Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term double-blind safety extension of asenapine in bipolar I disorder (P05692)
2010-018410-78Phase 3Completed
- Sponsor
- Schering-Plough Research Institute
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of asenapine in bipolar I disorder (2 arms), sponsored by Schering-Plough Research Institute. Primary endpoint: Long-term safety of asenapine. Started May 2012; status: completed.
02
Drugs
asenapine
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on 2010-018410-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018410-78.